Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125687311 | 12568731 | 1 | I | 20160214 | 20160513 | 20160719 | 20160719 | EXP | IT-CIPLA LTD.-2016IT06766 | CIPLA | 0.00 | Y | 0.00000 | 20160719 | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125687311 | 12568731 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | 289 MG, TOTAL | Y | 0 | 289 | MG | SOLUTION FOR INFUSION | ||||||
| 125687311 | 12568731 | 2 | SS | Pemetrexed | PEMETREXED | 1 | Intravenous (not otherwise specified) | 547 MG TOTAL | Y | 0 | 547 | MG | SOLUTION FOR INFUSION | ||||||
| 125687311 | 12568731 | 3 | C | JAKAFI | RUXOLITINIB | 1 | Oral | 10 MG, UNK | U | U | 0 | 10 | MG | TABLET | |||||
| 125687311 | 12568731 | 4 | C | Pantorc | PANTOPRAZOLE SODIUM | 1 | Oral | 40 MG, UNK | U | U | 0 | 40 | MG | CAPSULE | |||||
| 125687311 | 12568731 | 5 | C | Zyloric | ALLOPURINOL | 1 | Oral | 150 MG, UNK | U | U | 0 | 150 | MG | TABLET | |||||
| 125687311 | 12568731 | 6 | C | Omnic | TAMSULOSIN HYDROCHLORIDE | 1 | Oral | 0.4 MG, UNK | U | U | 0 | .4 | MG | CAPSULE | |||||
| 125687311 | 12568731 | 7 | C | MOVICOL | POLYETHYLENE GLYCOL 3350POTASSIUM CHLORIDESODIUM BICARBONATESODIUM CHLORIDE | 1 | Oral | 13.8 G | U | U | 0 | ||||||||
| 125687311 | 12568731 | 8 | C | ZOLOFT | SERTRALINE HYDROCHLORIDE | 1 | Oral | 25 MG, UNK | U | U | 0 | 25 | MG | TABLET | |||||
| 125687311 | 12568731 | 9 | C | Cardioaspirin | ASPIRIN | 1 | Oral | 100 MG, UNK | U | U | 0 | 100 | MG | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125687311 | 12568731 | 1 | Lung neoplasm malignant |
| 125687311 | 12568731 | 2 | Lung neoplasm malignant |
| 125687311 | 12568731 | 3 | Myelofibrosis |
| 125687311 | 12568731 | 4 | Gastrooesophageal reflux prophylaxis |
| 125687311 | 12568731 | 5 | Hyperuricaemia |
| 125687311 | 12568731 | 6 | Benign prostatic hyperplasia |
| 125687311 | 12568731 | 7 | Astringent therapy |
| 125687311 | 12568731 | 8 | Depression |
| 125687311 | 12568731 | 9 | Thrombosis prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125687311 | 12568731 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125687311 | 12568731 | Anaemia | |
| 125687311 | 12568731 | Cough | |
| 125687311 | 12568731 | Neutropenia | |
| 125687311 | 12568731 | Pyrexia | |
| 125687311 | 12568731 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125687311 | 12568731 | 1 | 20160208 | 20160208 | 0 | |
| 125687311 | 12568731 | 2 | 20160208 | 20160208 | 0 |